HK Stock Market Move | CLOUDBREAK-B(02592) dropped nearly 15% once. CBT-199, an ophthalmology candidate drug, has submitted a new drug clinical trial application in the United States.

CLOUDBREAK-B (02592) once fell by nearly 15%, and has retreated by over 40% since December 5. It is worth noting that the stock saw a significant surge from November 21 to December 4, with the stock price doubling in just 10 trading days. At the time of writing, it is down 11.59% to 4.96 Hong Kong dollars, with a trading volume of 6.7798 million Hong Kong dollars. On the news front, Bo Kang Vision announced that on December 15, its wholly-owned subsidiary ADS Therapeutics LLC submitted a new drug clinical trial application for CBT-199 (a potential best-in-class ophthalmic candidate drug developed by the Group) to the U.S. Food and Drug Administration. CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, and the results of these studies are expected to contribute to future clinical trials. It is also noteworthy that on January 3, Bo Kang Vision's two cornerstone investors will see their lock-up shares released.